Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

US market

This page shows the latest US market news and features for those working in and with pharma, biotech and healthcare.

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Oxycodone is the active ingredient of recently bankrupted Purdue Pharma’s OxyContin, a drug which had taken much of the brunt of blame for the opioid addiction epidemic in the US. ... sale of Aximris in the US market, or that it will ever be

Latest news

  • BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

    This approval was also noteworthy because it was the first for a Chinese-developed cancer drug in the US. ... Imbruvica made over $4bn in sales in the US market alone last year, and remains the clear market leader despite some encroachment from Calquence.

  • Mylan, Biocon’s Herceptin biosimilar launched in US Mylan, Biocon’s Herceptin biosimilar launched in US

    At least four other biosimilar Herceptin products are due to reach the US market by the end of the year and into early 2020, which will expose around 50% of sales ... Mylan/Biocon’s  Herceptin biosimilar is the second to launch in the US after

  • Private equity firm backs Ferring gene therapy venture Private equity firm backs Ferring gene therapy venture

    FerGene will operate as a subsidiary of Ferring, and will focus initially on bringing the gene therapy to the US market and continuing its clinical development elsewhere. ... Bringing a novel gene therapy to the market requires dedicated focus and

  • BeiGene bags FDA approval for first product Brukinsa in lymphoma BeiGene bags FDA approval for first product Brukinsa in lymphoma

    stage. It’s just the first of several cancer drugs BeiGene is hoping to bring to the US market. ... First-to-market Imbruvica made more than $4bn in sales in the US market alone last year and remains the clear market leader despite some encroachment

  • Novartis makes case for NASH candidate tropifexor Novartis makes case for NASH candidate tropifexor

    The winning player will reap the rewards of an untapped market – NASH affects up to 50 million people in the US alone, and market analysts Research and Markets  estimate that the ... market potential will reach $20.68bn by 2025, when the first

More from news
Approximately 1 fully matching, plus 804 partially matching documents found.

Latest Intelligence

  • The Golden Goose The Golden Goose

    The significance of the US market is also why Ehrlich, along with many others on the business/ marketing side of the industry, has little faith that importing cheaper drugs into the ... Drug-makers will not allow their golden goose US market to be

  • It’s not the end of the world, is it? It’s not the end of the world, is it?

    the US market when they would, de facto, be barred from other developed and price-controlled markets. ... It would have a disproportionate effect, for example, on companies who depend heavily on the US market.

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    The chosen candidate is then expected to gain approval in the US market in the first half of 2020, followed by Europe in the first half of 2021. ... Y. Katherine Xu, an analyst at William Blair, forecast peak annual sales of $10.2bn, up from $8.9bn

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Almost all sales come from the US market, mainly because of supply constraints for Cinryze in recent years, something that the combined company will aim to address. ... In the long term, a US market share of 10% of the number of patients treated, or

  • Is China ready for a pharmaceutical gold rush?

    Rapidly growing sector. The US alone holds over 45% of the global pharmaceutical market. ... Indeed, BMS will pitch Opdivo at half the US list price, determining the true value of market access.

More from intelligence
Approximately 0 fully matching, plus 49 partially matching documents found.

Latest appointments

  • New faces at 11 London, ramarketing and MSL New faces at 11 London, ramarketing and MSL

    The new office in Cambridge, Massachusetts, will give ramarketing a presence in the growing pharma and biotech hub and a foothold in the US market, allowing it to locally service its ... Emma’s insight into the global life sciences sector means she

  • Pharma industry appointments Pharma industry appointments

    Prior to this, Jenkins spent 17 years at GlaxoSmithKline (GSK) in the UK and US. ... UK. Vu, whose new post will see him further expand Concept’s presence in the US market, joins the company with over 15 years’ experience in both business development

  • Open Health creates new role Open Health creates new role

    Joining the agency with twenty years’ biopharmaceutical industry experience, Jones’ expertise lies in market access, therapy launch and patient centric services. ... Creating a unique role within our field of expertise will enable us to offer a

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications offering.

  • Amra appoints new VP of North American sales Jeremy Edwards Amra appoints new VP of North American sales Jeremy Edwards

    With more than 20 years’ experience in the clinical development industry, Edwards joins the company after spending five years as vice president and general manager of the US operations for Exco ... expand the US market.”.

More from appointments
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest from PMHub

  • Emotional Recognition using Facial Analysis

    According to psychologists, a lot of emotional information can be drawn from our facial expressions, which is valuable to us as market researchers as we are interested in the emotional responses

  • RWE Blog 2: Payers use real-world data cautiously

    Ready to use real-world evidence to its full potential to improve market access to your product? ... Call us on: 44 (0) 20 3750 9833 or email us at:  discover@validinsight.com.

  • RWE Blog 1: Real-world challenges and real-world data

    This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access. ... Take advantage of Valid Insight’s expertise to help you best understand how to use RWE for market access by calling us:

  • Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019 Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019

    Our team of Market Access, Pricing and HEOR experts will be available throughout the event at booth C2-006 which will be held in Copenhagen, Denmark. ... If you would like to book a meeting, at the event, with one of our experts and learn more about how

  • Spotlight interview: 15 minutes on PR in pharma Spotlight interview: 15 minutes on PR in pharma

    the coming together of strong, iconic legacy healthcare agencies with deep specialisms in advertising, PR, patient engagement and market research, OPEN Health PBC is unique in its ability to deploy ... 5.  GIVE US SOME EXAMPLES OF GREAT WORK YOU HAVE

More from PMHub
Approximately 0 fully matching, plus 38 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Quick links

Infographics

Multimedia